### III. The Official Record

The official records are electronic records.

Dated: May 14, 2025.

**Alisa Zimmerman,**

*Deputy General Counsel.*

[FR Doc. 2025–08913 Filed 5–19–25; 8:45 am]

**BILLING CODE 6732–01–P**

## FEDERAL MEDIATION AND CONCILIATION SERVICE

### Succession Plan for the Federal Mediation and Conciliation Service

**AGENCY:** Federal Mediation and Conciliation Service (FMCS).

**ACTION:** Notice of succession plan for the FMCS.

**SUMMARY:** The Federal Mediation and Conciliation Service, is issuing this notice to inform the public of the succession plan for the Federal Mediation and Conciliation Service provided by the Director of FMCS. This notice supersedes all prior succession plans issued by the agency for officials performing the functions and duties of the Director of FMCS.

**DATES:** This Succession Plan for the FMCS is effective May 20, 2025.

**FOR FURTHER INFORMATION CONTACT:** For specific questions related to this notice, please contact Greg Goldstein, 202–606–8111, *ggoldstein@fmcs.gov.*

**SUPPLEMENTARY INFORMATION:** By the authority vested in the Director of the Federal Mediation and Conciliation Service by 29 U.S.C. 172, and to provide for the continuity of essential operations of the FMCS in all circumstances this notice provides the succession plan of officials authorized to perform the functions and duties of the Director of the Federal Mediation and Conciliation Service. The following is the succession plan of officials hereby ordered:

### Order of Succession

During any period in which the Director has died, resigned, or otherwise become unable to perform the functions and duties of the office of the Director, and there is no Acting Director serving under the Federal Vacancies Reform Act of 1998, 5 U.S.C. 3345–3349d, the following officers of the FMCS, in the order listed, are hereby delegated the authority to perform the functions and duties of the Director, to the extent permitted by law:

1. Principal Deputy, Chief Operating Officer;
2. General Counsel;
3. Director, Operational Security and Continuity of Operations;
4. Director, Human Resources;
5. Deputy General Counsel.

No individual who is serving in an office listed in this order in an acting capacity, by virtue of so serving, shall be delegated the functions and duties of the Director.

Dated: May 14, 2025.

**Gregory Goldstein,**

*Acting Director.*

[FR Doc. 2025–08978 Filed 5–19–25; 8:45 am]

**BILLING CODE 6732–01–P**

## FEDERAL MEDIATION AND CONCILIATION SERVICE

### Arbitrator's Report and Fee Statement

**AGENCY:** Federal Mediation and Conciliation Service (FMCS).

**ACTION:** 30-Day notice and request for comments.

**SUMMARY:** The Federal Mediation and Conciliation Service (FMCS), invites the public and other Federal Agencies to take this opportunity to comment on the following information collection request, Arbitrator's Report and Fee Statement, FMCS Form R–19. This information collection request will be submitted for approval to the Office of Management Budget (OMB) in compliance with the Paperwork Reduction Act (PRA). The Arbitrator's Report and Fee Statement, FMCS Form R–19, allows FMCS to comply with its statutory obligation to make governmental facilities available for voluntary arbitration. To carry out this policy, FMCS has issued regulations which provide for the operation and maintenance of a roster of professional arbitrators. The FMCS Form R–19, which arbitrators file with the Agency following each decision rendered, allows FMCS to monitor the work of the Arbitrator and to collect arbitration information, such as median arbitrator fees and days spent on each case, for the Agency's annual report.

**DATES:** Comments must be submitted on or before June 20, 2025.

**ADDRESSES:** You may submit comments, identified by Arbitrator's Report and Fee Statement (FMCS Form R–19), through one of the following methods:

- *Email: register@fmcs.gov;*
- *Mail:* Office of General Counsel, One Independence Square, 250 E St. SW, Washington, DC 20427.

**FOR FURTHER INFORMATION CONTACT:** Karen Pierce, 202–606–3672, *kpierce@fmcs.gov.*

**SUPPLEMENTARY INFORMATION:** Copies of the agency form are available here. Paper copies are available from the Office of Client Services by emailing Karen Pierce at the email address above. Please ask for the Arbitrator's Report and Fee Statement (FMCS Form R–19).

### I. 60-Day Comment Period

FMCS published a **Federal Register** notice, with a 60-day public comment period soliciting comments, of the following collection of information on March 7, 2025, 90 FR 11541. FMCS received no comments.

### II. Request for Comments

FMCS solicits comments to:

i. Evaluate whether the proposed collections of information are necessary for the proper performance of the functions of the agency, including whether the information will have practical utility.

ii. Enhance the accuracy of the agency's estimates of the burden of the proposed collection of information.

iii. Enhance the quality, utility, and clarity of the information to be collected.

iv. Minimize the burden of the collections of information on those who are to respond, including the use of appropriate automated, electronic collection technologies or other forms of information technology.

### III. Information Collection Request

*Agency:* Federal Mediation and Conciliation Service.

*Title:* Arbitrator's Report and Fee Statement (FMCS Form R–19).

*OMB Number:* 3076–0003.

*Type of Request:* Extension without change of a currently approved collection.

*Affected Public:* Private Sector to include businesses or other for-profits.

*Frequency:* Once a year, on occasion.

*Burden:* The total annual burden estimate is that FMCS will receive approximately 2,000 responses per year, one response per year. This form takes about 5 minutes to complete.

### Information Collection Requirement

*Purpose and Description of Data Collection*

Pursuant to 29 U.S.C. 171(b) and 29 CFR part 1404, FMCS assumes responsibility to monitor the work of the arbitrators who serve on its Roster. This is satisfied by requiring the completion and submission of a Report and Fee Statement, which indicates when the arbitration award was rendered, the file number, the company and union, the issues, whether briefs were filed and transcripts taken, if there were any waivers by parties on the date the award was due, and the fees and days for services of the arbitrator.

Use of Results

FMCS publishes this information in the agency's annual report, to inform the public about the arbitration services program and certain national trends in arbitration.

**IV. The Official Record**

The official records are electronic records.

Dated: May 14, 2025.

**Alisa Zimmerman,**

*Deputy General Counsel.*

[FR Doc. 2025–08912 Filed 5–19–25; 8:45 am]

**BILLING CODE 6732–01–P**

## FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

### Notice of Board Meeting

**DATES:** May 29, 2025 at 10:00 a.m. ET.

**ADDRESSES:** Telephonic. Dial-in (listen only) information: Number: 1–202–599–1426, Code: 529 856 22#; or via web: *https://www.frtib.gov/*.

**FOR FURTHER INFORMATION CONTACT:** James Kaplan, Director, Office of External Affairs, (202) 864–7150.

**SUPPLEMENTARY INFORMATION:**

**Board Meeting Agenda**

*Open Session*

1. Approval of the April 22, 2025, Board Meeting Minutes
2. Approval of the November 14, 2024, ETAC Meeting Minutes
3. Monthly Reports
   (a) Participant Report
   (b) Investment Report
   (c) Legislative Report
4. Quarterly Reports
   (c) Metrics
5. OPE Office Presentation

*Closed Session*

6. Information covered under 5 U.S.C. 552b(c)(9)(B) and (c)(10).

*Authority:* 5 U.S.C. 552b(e)(1).

Dated: May 15, 2025.

**Dharmesh Vashee,**

*General Counsel, Federal Retirement Thrift Investment Board.*

[FR Doc. 2025–09009 Filed 5–19–25; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. FDA–2025–N–1110]**

### Dihydropyrimidine Dehydrogenase Deficiency and the Use of Fluoropyrimidine Chemotherapy Drugs; Establishment of a Public Docket; Request for Comments

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; establishment of a public docket; request for comments.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is announcing the establishment of a docket to solicit public comment for information on dihydropyrimidine dehydrogenase (DPD) deficiency and the use of fluorouracil and capecitabine (both fluoropyrimidine chemotherapy drugs). The purposes of the docket establishment are to foster Agency transparency and to solicit input on the currently available information on DPD deficiency and the use of fluorouracil and capecitabine.

**DATES:** Submit either electronic or written comments by June 20, 2025.

**ADDRESSES:** You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before June 20, 2025. The *https://www.regulations.gov* electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of June 20, 2025. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

You may submit comments as follows:

*Electronic Submissions*

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov*. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov*.
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

*Written/Paper Submissions*

Submit written/paper submissions as follows:

- *Mail/Hand delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

*Instructions:* All submissions received must include the Docket No. FDA–2025–N–1110 for ''Dihydropyrimidine Dehydrogenase Deficiency and the Use of Fluoropyrimidine Chemotherapy Drugs; Establishment of a Public Docket; Request for Comments.'' Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

- Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ''THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' FDA will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov*. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information be made publicly available, you can provide this information on the cover sheet and not